ZVAA Stock Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.28 |
| 52 Week High | €3.22 |
| 52 Week Low | €0.91 |
| Beta | 3.13 |
| 1 Month Change | -0.87% |
| 3 Month Change | -8.80% |
| 1 Year Change | 37.35% |
| 3 Year Change | -85.10% |
| 5 Year Change | -86.82% |
| Change since IPO | -93.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| ZVAA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 1.8% | -0.2% | 0.5% |
| 1Y | 37.3% | -22.8% | 1.3% |
Return vs Industry: ZVAA exceeded the German Biotechs industry which returned -23% over the past year.
Return vs Market: ZVAA exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| ZVAA volatility | |
|---|---|
| ZVAA Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ZVAA has not had significant price volatility in the past 3 months.
Volatility Over Time: ZVAA's weekly volatility has decreased from 24% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 234 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.
Cellectis S.A. Fundamentals Summary
| ZVAA fundamental statistics | |
|---|---|
| Market cap | €170.77m |
| Earnings (TTM) | -€67.01m |
| Revenue (TTM) | €22.86m |
7.5x
P/S Ratio-2.5x
P/E RatioIs ZVAA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZVAA income statement (TTM) | |
|---|---|
| Revenue | US$24.53m |
| Cost of Revenue | US$1.26m |
| Gross Profit | US$23.26m |
| Other Expenses | US$95.15m |
| Earnings | -US$71.89m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 94.86% |
| Net Profit Margin | -293.13% |
| Debt/Equity Ratio | 41.4% |
How did ZVAA perform over the long term?
See historical performance and comparison